FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113258486> ?p ?o ?g. }

• W2113258486 endingPage "S314" @default.
• W2113258486 startingPage "S309" @default.
• W2113258486 abstract "The original trials of empiric intravenous amphotericin-B in the 1980s failed to prove conclusively its efficacy in the treatment of febrile neutropenia. Despite that, all subsequent studies of the therapy of presumed, possible, probable and proven invasive aspergillosis have assumed that this drug, either as deoxycholate or in lipid-based form, is the gold standard treatment against which all newcomers should be compared. This has led to a series of further inconclusive randomized controlled trials of empiric therapy as a result of which the most we can say is that nearly all new drugs are less toxic but also no more effective than amphotericin-B deoxycholate. The toxicity of the non-lipid formulation of this drug should have led us to withdraw it from both RCTs and routine clinical practice some years ago in view of the increasing evidence of equivalent efficacy and lower toxicity of other agents including lipid amphotericin formulations.Recent studies of the use of newer diagnostic techniques (i.e., CT and serology) reinforce the need to abandon the empiric trial approach in which we have repeatedly shown lack of superiority in the treatment of an infection which most patients do not have. Even in the small number of trials of the therapy of proven or probable invasive aspergillosis, results have been inconclusive or at best confusing in trying to find a better option than amphotericin-B. The trial of voriconazole versus amphotericin-B deoxycholate for this indication is a model for study for all those interested in the difficulties of designing trials which lead to convincing results.Effective prophylaxis trials and their analyses began by following a more rational pathway, first showing convincingly that fluconazole reduced the risk of C. albicans systemic infection in transplant patients. Unfortunately the widespread faith in the ability of this drug to prevent a wider range of systemic fungal infections in a wider range of patients is simply not supported by the data from many subsequent single trials and meta-analyses. This attachment to fluconazole has been mirrored by unwillingness to accept the evidence that itraconazole is superior in prophylaxis to fluconazole which is inactive against Aspergillus spp. In this case the trials have not told us enough because we have not believed the results. Results of trials of extended range azoles such as posaconazole are interesting but there are insufficient data to claim that posaconazole is superior to itraconazole.The progress in therapy and prophylaxis of systemic fungal infection has been unsatisfactory and slow. A new approach is needed for the design of clinical trials for these indications. There is good evidence that supportive investigations should now be used routinely in clinical practice and trials to increase certainty about the presence of invasive infection, to limit unnecessary use of expensive and toxic drugs and to improve analysis of efficacy of old and new antifungal agents." @default.
• W2113258486 created "2016-06-24" @default.
• W2113258486 creator A5086843769 @default.
• W2113258486 date "2006-09-01" @default.
• W2113258486 modified "2023-10-14" @default.
• W2113258486 title "The debate: The trials have told us very little" @default.
• W2113258486 cites W134773975 @default.
• W2113258486 cites W1497525379 @default.
• W2113258486 cites W1510894502 @default.
• W2113258486 cites W1969880613 @default.
• W2113258486 cites W1971548861 @default.
• W2113258486 cites W1976941151 @default.
• W2113258486 cites W1980337773 @default.
• W2113258486 cites W1986330094 @default.
• W2113258486 cites W1989277463 @default.
• W2113258486 cites W2006530253 @default.
• W2113258486 cites W2029714817 @default.
• W2113258486 cites W2035960777 @default.
• W2113258486 cites W2037242084 @default.
• W2113258486 cites W2047037815 @default.
• W2113258486 cites W2068893995 @default.
• W2113258486 cites W2072268052 @default.
• W2113258486 cites W2078654597 @default.
• W2113258486 cites W2081707092 @default.
• W2113258486 cites W2082695689 @default.
• W2113258486 cites W2096480959 @default.
• W2113258486 cites W2097394217 @default.
• W2113258486 cites W2114208000 @default.
• W2113258486 cites W2129948097 @default.
• W2113258486 cites W2133328722 @default.
• W2113258486 cites W2139678747 @default.
• W2113258486 cites W2146052740 @default.
• W2113258486 cites W2149546447 @default.
• W2113258486 cites W2163206122 @default.
• W2113258486 cites W2167412063 @default.
• W2113258486 cites W2170019085 @default.
• W2113258486 cites W2233665167 @default.
• W2113258486 cites W2326799365 @default.
• W2113258486 cites W2559352377 @default.
• W2113258486 cites W2980289908 @default.
• W2113258486 cites W4252230400 @default.
• W2113258486 cites W4300693245 @default.
• W2113258486 doi "https://doi.org/10.1080/13693780600902235" @default.
• W2113258486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30408922" @default.
• W2113258486 hasPublicationYear "2006" @default.
• W2113258486 type Work @default.
• W2113258486 sameAs 2113258486 @default.
• W2113258486 citedByCount "0" @default.
• W2113258486 crossrefType "journal-article" @default.
• W2113258486 hasAuthorship W2113258486A5086843769 @default.
• W2113258486 hasBestOaLocation W21132584861 @default.
• W2113258486 hasConcept C126322002 @default.
• W2113258486 hasConcept C142724271 @default.
• W2113258486 hasConcept C16005928 @default.
• W2113258486 hasConcept C168563851 @default.
• W2113258486 hasConcept C177713679 @default.
• W2113258486 hasConcept C203014093 @default.
• W2113258486 hasConcept C204787440 @default.
• W2113258486 hasConcept C2776391196 @default.
• W2113258486 hasConcept C2777063308 @default.
• W2113258486 hasConcept C2779181126 @default.
• W2113258486 hasConcept C2779548794 @default.
• W2113258486 hasConcept C2779629538 @default.
• W2113258486 hasConcept C2780402444 @default.
• W2113258486 hasConcept C2780690907 @default.
• W2113258486 hasConcept C2909039274 @default.
• W2113258486 hasConcept C29730261 @default.
• W2113258486 hasConcept C40993552 @default.
• W2113258486 hasConcept C535046627 @default.
• W2113258486 hasConcept C71924100 @default.
• W2113258486 hasConceptScore W2113258486C126322002 @default.
• W2113258486 hasConceptScore W2113258486C142724271 @default.
• W2113258486 hasConceptScore W2113258486C16005928 @default.
• W2113258486 hasConceptScore W2113258486C168563851 @default.
• W2113258486 hasConceptScore W2113258486C177713679 @default.
• W2113258486 hasConceptScore W2113258486C203014093 @default.
• W2113258486 hasConceptScore W2113258486C204787440 @default.
• W2113258486 hasConceptScore W2113258486C2776391196 @default.
• W2113258486 hasConceptScore W2113258486C2777063308 @default.
• W2113258486 hasConceptScore W2113258486C2779181126 @default.
• W2113258486 hasConceptScore W2113258486C2779548794 @default.
• W2113258486 hasConceptScore W2113258486C2779629538 @default.
• W2113258486 hasConceptScore W2113258486C2780402444 @default.
• W2113258486 hasConceptScore W2113258486C2780690907 @default.
• W2113258486 hasConceptScore W2113258486C2909039274 @default.
• W2113258486 hasConceptScore W2113258486C29730261 @default.
• W2113258486 hasConceptScore W2113258486C40993552 @default.
• W2113258486 hasConceptScore W2113258486C535046627 @default.
• W2113258486 hasConceptScore W2113258486C71924100 @default.
• W2113258486 hasIssue "Supplement_1" @default.
• W2113258486 hasLocation W21132584861 @default.
• W2113258486 hasLocation W21132584862 @default.
• W2113258486 hasOpenAccess W2113258486 @default.
• W2113258486 hasPrimaryLocation W21132584861 @default.
• W2113258486 hasRelatedWork W1973564586 @default.
• W2113258486 hasRelatedWork W1977277955 @default.
• W2113258486 hasRelatedWork W2020981089 @default.
• W2113258486 hasRelatedWork W2028197004 @default.

• next